Zacks Investment Research (Celgene Corp.: NASDAQ) shares fell on Wednesday Dec 28 with lower trade volume than normal after a number of analysts weighed in on the investing value of the stock with a downgraded rating.
Meanwhile, U.S. stocks were little changed on Wednesday, as investors found few reasons to keep pushing shares higher towards the 20,000 mark.
The Dow Jones Industrial Average DJIA, -0.11% rose 3.1 points to 19,949, essentially unchanged on the day. The S&P 500 SPX, -0.39% lost 3 points, or 0.1%, to 2,266 while the Nasdaq Composite Index COMP, -0.59% slipped 6.4 points, or 0.1%, to 5,482.
Analysts at Zacks Investment Research downgraded shares of Zacks Investment Research (Celgene Corp.: NASDAQ) from Buy to Hold in a research note to investors today. With a rating of Hold on the stock, Celgene Corp. has a 52-week high of $127.00. The one-year price target of $138.04 is higher than the opening price of $117.86, causing a number of other analysts to report on the company recently. Downgrades are more likely when analysts consider that the future prospects for the security have diminished from the initial recommendation, usually caused by a material and fundamental digression in the company’s actions, future direction or industry.
Zacks Investment Research (Celgene Corp.: NASDAQ) shares last traded at $117.42, which represents a dip of $0.51 per share or -0.43% from the previous closing price. Opening at $117.86, they ranged from $117.25 and $117.91 throughout the day.
Zacks Investment Research (Celgene Corp.: NASDAQ) now has a market cap of 91.02B.
Zacks Investment Research (Celgene Corp.: NASDAQ) Average Daily Trading Volume
The stock’s average daily volume is 4,750,230 shares out of a total float 773,428,000 and some 230,756 shares crossed the trading desk yesterday, lower than normal. Swing traders often use upticks in trading volume to pinpoint substantial volume aggregation or distribution by institutional investors, so trading volume is likely to increase in the next few days.
While increased trading for one day will not mean much, however, a trend of heavy trading volume on the buy side over a series of days or weeks delivers a positive signal to market traders that institutions may be moving in, so institutional sponsorship is very important.
Institutional sponsorship is defined by ownership of a stock by mutual funds, banks, pension funds and other large institutions.
These professional investors retain teams of analysts researching thousands of stocks. Thus, watching their interests is a good way to ensure you are buying the right stocks.
Zacks Investment Research (Celgene Corp.: NASDAQ) Moving Averages
A moving average can also act as support or resistance. In an uptrend a 50-day, 100-day or 200-day moving average may act as a support level, as shown in the figure below.
This is because the average acts like a floor (support), so the price bounces up off of it.
In a downtrend a moving average may act as resistance; like a ceiling, the price hits it and then starts to drop again.
By identifying trends, moving averages allow traders to make those trends work in their favor and increase the number of successful trades.
Trades for Zacks Investment Research (Celgene Corp.: NASDAQ) have ranged from $93.05 – 127.000, and the stock now has a 50-day MA of $118.08 and 200-day MA of $108.52. Today’s last price is 7.55%% below the 52 week high of $127.00.
Earnings growth is a critical factor to research when investing in stocks and investors seek companies that have raised their earnings by at least 25% for the past 3 years.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of the website. Readers should not consider statements made by the author as formal recommendations and should consult their financial adviser before making any investment decisions. To read our full disclosure, please see our terms and conditions page.